Global Antibody Drug Conjugates (ADC) Market By Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Indication (Lymphoma, Breast Cancer, Brain Tumor, Lung Cancer, Ovarian Cancer, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027.
Market Analysis and Insights: Global Antibody Drug Conjugates (ADC) Market
Antibody drug conjugates (ADC) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of cancer related disorders worldwide and emerging markets are the factors responsible for the growth of this market.
Growing cases of breast cancer in female, increased research and clinical trials and rising prevalence of cancer worldwide will boost up the antibody drug conjugates (ADC) market. But, stringent FDA guidelines for the drug approval of new drug & adverse effect after the treatment may hamper the global antibody drug conjugates (ADC) market.
Antibody drug conjugates are the biopharmaceuticals agents designed as targeted therapy of cancer treatment. Antibody drug conjugates are covalently linked to the antibody or antibody fragment that directed towards the specific cell surface target expressed on the tumor cells. They are combined with monoclonal antibodies to target the cancer cells. They act by specifically targeting to the tumor antigen surface, the complex internalized into the cells. Following internalization, internalized fuse vesicles enters into the endosomes- lysosome pathways, in with mild acidic environment digest the antibodies to release free payload and enters into the cytoplasm by crossing the lysosome membrane. This conjugation process binds to the target and lead to the cell death.
This antibody drug conjugates (ADC) market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Antibody Drug Conjugates (ADC) Market Scope and Market Size
The antibody drug conjugates (ADC) market is segmented on the basis of target, indication, end-users and distribution channel.
- On the basis of target, the market is segmented into antibody-protein toxin conjugates, antibody-chelated radionuclide conjugates, antibody-small-molecule drug conjugates and antibody-enzyme conjugates
- The indication for antibody drug conjugates (ADC) market includes lymphoma, breast cancer, brain tumor, lung cancer, ovarian cancer and others
- On the basis of end-users, the market is segmented into hospitals, specialty clinics and others
- On the basis of distribution channel, the market has also been segmented into hospital pharmacy, retail pharmacy, others
Antibody Drug Conjugates (ADC) Market Country Level Analysis
Antibody drug conjugates (ADC) market are analysed and market size information is provided by country, type, indication, end-users and distribution channel as referenced above.
The countries covered in the antibody drug conjugates (ADC) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, U.A.E, Egypt, Saudi Arabia, Israel, Kuwait, South Africa, Rest of Middle East and Africa, in Middle East and Africa.
North America accounts the largest market share due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals. Europe is considered to be second largest market for antibody drug conjugates due to increased cancer & bone marrow surgeries. Asia-Pacific is expected to account for the largest market share over coming years for the antibody drug conjugates (ADC) market due to increased government awareness programs and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Antibody drug conjugates (ADC) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Antibody Drug Conjugates (ADC) Market Share Analysis
Antibody drug conjugates (ADC) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to antibody drug conjugates (ADC) market.
The major players covered in the antibody drug conjugates (ADC) market are Seattle Genetics, Inc., Genentech Inc., Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd., Bristol -Myers Squibb, Merck & Co., Inc. Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED., and AbbVie Inc., among others.
Customization Available: Global Antibody Drug Conjugates (ADC) Mrket
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.